COLYTE w. FLAVOR PACKS Rx
Generic Name and Formulations:
Polyethylene glycol 3350 60g, sodium chloride 1.46g, potassium chloride 0.745g, sodium bicarbonate 1.68g, sodium sulfate 5.68g, flavor 0.851g/pack (orange, lemon lime, cherry); per liter of soln; pwd for reconstitution (add 1 flavor pack before reconstitution).
Indications for COLYTE w. FLAVOR PACKS:
Bowel cleansing before colonoscopy or barium enema exam.
After fasting for >3hrs, 240mL orally every 10mins or 20–30mL/min by NG tube until fecal discharge is clear. Usual dose 3–4L. Only clear liquids until exam.
GI obstruction or perforation. Gastric retention. Toxic colitis. Toxic megacolon. Ileus.
Severe ulcerative colitis. Impaired gag reflex. Semi- or unconsciousness. Risk of aspiration or regurgitation. Correct fluid and electrolyte abnormalities prior to initiation. Increased risk of arrhythmias (eg, history of prolonged QT, uncontrolled arrhythmias, recent MI, unstable angina, CHF or cardiomyopathy); do pre-dose and post-colonoscopy ECGs. History of seizures. Rule out GI obstruction or perforation. Maintain adequate hydration. Renal impairment. Pregnancy (Cat.C). Nursing mothers.
Isosmotic bowel cleanser.
Concomitant drugs that may increase the risk of fluid and electrolyte disturbances or adverse events. Drugs administered within 1hr of start of Colyte may not be absorbed. Increased risk of ischemic colitis with concomitant stimulant laxatives.
Nausea, abdominal fullness or bloating, cramps, vomiting, anal irritation; serious: colonic mucosal ulceration, ischemic colitis; rare: arrhythmias.
Colyte w. Flavor Packs—4L (disposable jug w. 3 flavor packs)
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Tools to Address the Opioid Crisis
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- Nonsinogenic Headache vs Chronic Rhinosinusitis Differential Diagnosis Based on SNOT-22 Patterns
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Factors Promoting Participation in Self-Management Training Program for Chronic Pain
- Gendered Perceptions of Socially Acceptable Pain Relief Strategies
- Majority of Internists Still Have Financial Ties to Industry